HHS' 2018 Greatest Hits: Azar Touts Record FDA Generic Approvals, Drug Pricing And Opioid Actions

In State of the Department speech and HHS annual report, Secretary Azar trumpets historic number of approvals by FDA, and price cuts, roll backs or freezes by 'more than a dozen drug companies.'